As a lecturer, Camiel Boon will focus primarily on innovative clinical, translational and therapeutic research and highly specialised care for patients with hereditary ophthalmic diseases, both at the AMC-UvA and within national and international research networks. This research will take place at the AMC-UvA, which is an expertise centre for hereditary ophthalmic diseases and has one of the largest clinical and genetic databases in the world for such diseases. At the Leiden University Medical Center (LUMC), Boon is involved in the development of gene therapy for hereditary retinal diseases. In his role as professor of Clinical Ophthalmogenetics he will focus on strengthening the research collaboration between the LUMC and the AMC-UvA. He will also be actively involved in teaching medical students, ophthalmologists and ophthalmologists in training.

Boon is a consultant ophthalmologist and clinician-scientist in the LUMC's Department of Ophthalmology. He was trained as an ophthalmologist at Radboud University Medical Center (Nijmegen, the Netherlands). After completing additional clinical and surgical fellowships in the Oxford University Eye Hospital and at the Rotterdam Eye Hospital, Boon is specialized in medical and surgical treatment of hereditary and other diseases of the retina. In 2009 he obtained his PhD with cum laude distinction from Radboud University Nijmegen, with a thesis entitled 'Hereditary retinal disease – Clinical and genetic studies on the role of the peripherin/RDS gene, the BEST1 gene, and the CFH gene'. For this thesis he received the Binkhorst Prize for best ophthalmological doctoral thesis from the Netherlands Ophthalmological Society (NOG) and the Best Thesis Award from the Nijmegen Center for Molecular Life Sciences. For his research on these and other hereditary ophthalmic diseases, he has received several awards, including the Gisela Thier Fellowship from Leiden University and a ZonMw Veni grant.

Boon is a fellow of the European Board of Ophthalmology, board member of the Medical Retina working group of the NOG, co-founder and board member of the European Young Retinal Specialists Society (YoungRetina) and founder of the international CHASE Consortium for clinical and genetic research on central serous chorioretinopathy. Boon is the initiator and principal researcher of multiple treatment trials for diseases of the retina. As an ophthalmologist he is also a member of the medical advisory council for various patient associations.